We have updated our Vicore model for the acquisition of INIM Pharma and Q2 results. We maintain and reiterate both our target price of SEK43 and OUTPERFORM recommendation, based on our view that Vicore's lead asset VP01 (C21) in Phase IIa for idiopathic pulmonary fibrosis ("IPF") has the potential to reach peak sales of c.$1.4bn by 2030E following regulatory approval in 2023E. INIM adds a promising preclinical asset, the IMiD ("immunomodulatory imide drugs") technology to develop local treatment ....
05 Sep 2018
Post INIM, focus remains on severe lung disease
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Post INIM, focus remains on severe lung disease
Vicore Pharma Holding AB (6Y4:FRA) | 0 0 0.0%
- Published:
05 Sep 2018 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
11
We have updated our Vicore model for the acquisition of INIM Pharma and Q2 results. We maintain and reiterate both our target price of SEK43 and OUTPERFORM recommendation, based on our view that Vicore's lead asset VP01 (C21) in Phase IIa for idiopathic pulmonary fibrosis ("IPF") has the potential to reach peak sales of c.$1.4bn by 2030E following regulatory approval in 2023E. INIM adds a promising preclinical asset, the IMiD ("immunomodulatory imide drugs") technology to develop local treatment ....